FAQs
Answers to FAQs about COMBIVENT RESPIMAT
Whether you are new to COMBIVENT RESPIMAT or simply want a refresher, look at frequently asked questions from the HCP community.
About COMBIVENT RESPIMAT
COMBIVENT RESPIMAT is a fast-acting bronchodilator (acts within 15 minutes) used to treat chronic obstructive pulmonary disease (COPD). It delivers 2 short-acting bronchodilators, ipratropium bromide and albuterol, that act by 2 different mechanisms. Working together, these 2 medicines do more to open airways than either medicine can do on its own.
No, COMBIVENT RESPIMAT is not a steroid.
COMBIVENT RESPIMAT is indicated for use in patients with chronic obstructive pulmonary disease who are on a regular aerosol bronchodilator and continue to have evidence of bronchospasm, requiring a second bronchodilator.
The soft mist of COMBIVENT RESPIMAT relaxes the muscles in the airways to help open them. And when used 4 times a day, every day, it helps keep them open.
The RESPIMAT inhaler delivers a soft, powder-free mist that allows patients to inhale slowly, even when breathing is difficult. The inhaler helps deliver nebulized small-particle-sized droplets deep into peripheral airways.*
*It is important to note that a correlation between lung deposition and clinical efficacy has not been established.
The most common (≥2%) adverse reactions seen with COMBIVENT RESPIMAT (20/100 mcg) are upper respiratory infection, nasopharyngitis, cough, bronchitis, headache, and dyspnea.
For many people with COPD, COMBIVENT RESPIMAT starts working 15 minutes after taking a dose.
Dosing and Administration
The recommended dosage is 1 inhalation 4 times a day, not to exceed 6 inhalations in 24 hours.
COMBIVENT RESPIMAT is administered through oral inhalation.
Patient Support
With the COMBIVENT RESPIMAT Savings Card, eligible patients pay as little as $35 for a 30-day prescription fill. Terms and Conditions Apply.
Time-tested, healthcare professional–trusted
Discover how COMBIVENT RESPIMAT has delivered relief and support over the decades.
The COMBIVENT RESPIMAT inhaler difference
Learn how the soft mist is delivered with ease.
Reference
- Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
COMBIVENT RESPIMAT is indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.
COMBIVENT RESPIMAT is contraindicated in patients hypersensitive to any of the ingredients of the drug product or to atropine or its derivatives.
COMBIVENT RESPIMAT can produce paradoxical bronchospasm that can be life-threatening. If it occurs, therapy with COMBIVENT RESPIMAT should be discontinued immediately and alternative therapy instituted.
The albuterol sulfate contained in COMBIVENT RESPIMAT can produce a clinically significant cardiovascular effect in some patients. If cardiovascular symptoms occur, COMBIVENT RESPIMAT may need to be discontinued.
COMBIVENT RESPIMAT should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
COMBIVENT RESPIMAT contains ipratropium bromide and may increase intraocular pressure which may result in precipitation or worsening of narrow-angle glaucoma. Use with caution in patients with narrow-angle glaucoma.
Patients should avoid spraying the aerosol into their eyes as this may cause acute eye pain or discomfort, temporary blurring of vision, mydriasis, visual halos, or colored images in association with red eyes from conjunctival or corneal congestion. Advise patients to consult their physician immediately if any of these symptoms develop while using COMBIVENT RESPIMAT.
Ipratropium bromide also may cause urinary retention.
Caution is advised when giving COMBIVENT RESPIMAT to patients with prostatic hyperplasia, or bladder-neck obstruction.
Since dizziness and blurred vision may occur with the use of COMBIVENT RESPIMAT, caution patients about engaging in activities such as driving a vehicle or operating appliances or machinery.
Do not exceed recommended dose. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma.
Hypersensitivity reactions including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema may occur. If such a reaction occurs, therapy with COMBIVENT RESPIMAT should be stopped at once and alternative treatment should be considered.
COMBIVENT RESPIMAT contains albuterol and should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus, and in patients who are unusually responsive to sympathomimetic amines. Albuterol may produce significant hypokalemia in some patients.
In clinical trials, the most common adverse reactions reported for COMBIVENT RESPIMAT were upper respiratory tract infection, nasopharyngitis, cough, bronchitis, headache, and dyspnea.
COMBIVENT RESPIMAT may interact additively with concomitantly used anticholinergic medications. Avoid co-administration with other anticholinergic-containing drugs.
Caution is advised in co-administration of other beta-adrenergic agents, beta-receptor blocking agents, and non-potassium sparing diuretics. Extreme caution is advised with monoamine oxidase inhibitors or tricyclic antidepressants.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
CL-CBR-100026 9.6.2022